Skip to search formSkip to main contentSkip to account menu

APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Objective: To review the design, efficacy, safety, dosing, therapeutic, and pharmacoeconomic considerations of sipuleucel-T, an… 
Review
2007
Review
2007
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to… 
Highly Cited
2006
Highly Cited
2006
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… 
Highly Cited
2006
Highly Cited
2006
APC8015 (sipuleucel‐T) is a cellular prostate cancer vaccine containing autologous antigen‐presenting cells (APC) loaded with… 
Review
2006
Review
2006
Sipuleucel-T (Provenge®; APC8015; Dendreon Corp, WA, USA) is a novel immunotherapeutic cellular product, which includes… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… 
Highly Cited
2004
Highly Cited
2004
Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen‐independent… 
Review
2002
Review
2002
  • B. Rini
  • Current opinion in molecular therapeutics
  • 2002
  • Corpus ID: 43594022
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC… 
Highly Cited
2000
Highly Cited
2000
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone…